JohnWayne... great minds think alike. that would all make sense, whether Gsk takes the entire Hervax package for themselves or a partnership / licensing deal going forward, either way it will push us into the big league , minimum 20_30c and like you say fully funds Pd1 and CF33 trials without another capital raise. All talk of cash in the bank should now at least factor in the A options, ~$6 million . Plus the B & C another ~$20 million over 2 years with sp above 5c.... Plus R&D rebates along the way.
The real question should be how much will a deal for HerVax add to the kitty, and how much will be paid back to shardholders via a distribution??? Suggest people do some homework on what these deals are really worth.
LC pro active investors interview, page-9
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.6¢ |
Change
-0.004(6.67%) |
Mkt cap ! $411.5M | |||
| Open | High | Low | Value | Volume |
| 5.9¢ | 5.9¢ | 5.5¢ | $1.481M | 26.09M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 400000 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 685507 | 4 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |